Back to Search Start Over

Individual and combined effects of peroxisome proliferator-activated receptor alpha and gamma agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.

Authors :
Wagner JA
Larson PJ
Weiss S
Miller JL
Doebber TW
Wu MS
Moller DE
Gottesdiener KM
Source :
Journal of Clinical Pharmacology; May2005, Vol. 45 Issue 5, p504-513, 10p
Publication Year :
2005

Abstract

This open-label, randomized, placebo-controlled, incomplete-block, 3-period crossover pilot study investigated the effects of peroxisome proliferator-activated receptor alpha- and gamma-agonists on biomarkers of lipid and glucose metabolism in 12 nondiabetic subjects. Plasma samples were collected before and after each 14-day treatment with placebo, fenofibrate (201 mg/d), rosiglitazone (4 mg twice daily), and combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily). Except for triglycerides (P < .042) and free fatty acids (P < .074), no significant interaction was demonstrated between fenofibrate and rosiglitazone; thus, the effect due to each drug alone was evaluated (presence/absence of drug). Fenofibrate significantly (P < .050) increased lipoprotein lipase activity (35%) and decreased apolipoproteins B (13%) and C-III (20%). Rosiglitazone significantly (P < .050) decreased fasting glucose (7.3%) and increased apolipoprotein C-III (19%) and adiponectin (137%). Fenofibrate and rosiglitazone also produced effects on triglycerides and free fatty acids, but it was not possible to determine if these effects were synergistic in nature. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00912700
Volume :
45
Issue :
5
Database :
Complementary Index
Journal :
Journal of Clinical Pharmacology
Publication Type :
Academic Journal
Accession number :
106366471